Connect with us

Biotech

The Government of Catalonia awards Roche a €9.2 million contract for analysis services

The Swiss pharmaceutical company Roche will supply reagents and consumables and will provide the necessary equipment to carry out analytical serological and biochemical determinations. The BST laboratory requires for its activity the performance of serology, biochemistry and immunohematology determinations in different types of human biological samples.

Published

on

This picture show a person doing some experiments.

The Catalan government has once again awarded a contract to the pharmaceutical giant Roche. The Government of Quim Torra has chosen the Swiss multinational to provide the Banc de Sang i Teixits (BST) with reagents and consumables for $10.8 million (€9.2 million), according to the profile of the contractor of the autonomous Executive. 

Over the next five years, Roche will supply BST with reagents and consumables and will provide the necessary equipment to carry out analytical serological, biochemical and immunohematology determinations in its laboratory. The amount required for 2020 is more than $1.18 million (€1 million), while for the remaining years it is up to $8.9 million (€7.6 million).

Prior to the formalization of the contract between the Catalan Government and Roche, the Government demanded a guarantee of $450,898 (€383,536.5) from the pharmaceutical company, in accordance with the resolution of the tender, signed by Enric Arguelagués, general manager of the Banc de Sang i Teixits.   

If you want to read more about the agreement between the Catalan Government and the Swiss biotech company Roche, download for free our companion app. Discover the world’s most interesting business headlines with the mobile app Born2Invest. The app provides its readers access to the latest news in global business, stock market, finance news, and also trending topics like bitcoin, cryptocurrency, and biotech.

The Catalan government has signed this contract with Roche for a period of five years

BST published a preliminary consultation on March 5th 2019 with the intention of analyzing the market situation and seeking a global solution for its transfusion safety laboratory, which would take into account the needs for analytical and pre-analytical automation. 

SEE ALSO  Nationwide toll transponder system could materialize in the next 3 years

The BST laboratory requires for its activity the performance of serology, biochemistry and immunohematology determinations in different types of human biological samples: peripheral blood, umbilical cord blood, serum and plasma, among others. The purpose of these studies is to guarantee the safety of donors and recipients and to ensure the quality of the products to be transfused or transplanted. 

The laboratory registers approximately 280,000 blood donations annually, plus 10,000 donations of other types, including cadaveric donors, bone marrow or umbilical cord donors. The entity currently has analysers on loan and in ownership to carry out these studies. 

However, in order to avoid technological obsolescence and to maintain the appropriate level of quality for the purpose of the studies, BST has entrusted Roche with the renewal of the analyzers. Last October, Roche signed a $11.9 million (€10.1 million) contract with the Catalan Institute of Health (ICS), a body under the Catalan government, to supply drugs for exclusive distribution. These drugs include Herceptin, aimed at combating early breast cancer; Esbriet, with indications for treating idiopathic pulmonary fibrosis; and Avastin, a drug that is also used in cases of vision loss due to age-related wet macular degeneration.

The Swiss biotech company’s sales registered a 1% increase in the first quarter of the year, and a 2% increase in the core earnings per share (EPS). However, overall, the coronavirus pandemic had a negative effect on Roche’s sales.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Desmond O’Flynn believes in minimalism and the power of beer. As a young reporter for some of the largest national publications, he has lived in the world of finance and investing for nearly three decades. He has since included world politics and the global economy in his portfolio. He also writes about entrepreneurs and small businesses, as well as innovation in fintech, gambling, and cannabis industries.